Pal, S K, Uzzo, R, Karam, J A, Master, V A, Donskov, F, Suarez, C, Albiges, L, Rini, B, Tomita, Y, Kann, A G, Procopio, G, Massari, F, Zibelman, M, Antonyan, I, Huseni, M, Basu, D, Ci, B, Leung, W, Khan, O, Dubey, S & Bex, A 2022, ' Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010) : a multicentre, randomised, double-blind, phase 3 trial ', The Lancet, vol. 400, no. 10358, pp. 1103-1116 . https://doi.org/10.1016/S0140-6736(22)01658-0